S. Zildjian

571 total citations
21 papers, 200 citations indexed

About

S. Zildjian is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, S. Zildjian has authored 21 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in S. Zildjian's work include Cancer Genomics and Diagnostics (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Genetic factors in colorectal cancer (5 papers). S. Zildjian is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Genetic factors in colorectal cancer (5 papers). S. Zildjian collaborates with scholars based in United States, United Kingdom and Spain. S. Zildjian's co-authors include James J. O’Leary, Asher Chanan‐Khan, Jeffrey L. Wolf, Steven Weitman, Mecide Gharibo, Sundar Jagannath, Sikander Ailawadhi, Albert Qin, Robert Vescio and Juan Garcia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

S. Zildjian

20 papers receiving 193 citations

Peers

Countries citing papers authored by S. Zildjian

Since Specialization

Citations

This map shows the geographic impact of S. Zildjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Zildjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Zildjian more than expected).

Fields of papers citing papers by S. Zildjian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Zildjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Zildjian. The network helps show where S. Zildjian may publish in the future.

Co-authorship network of co-authors of S. Zildjian

This figure shows the co-authorship network connecting the top 25 collaborators of S. Zildjian. A scholar is included among the top collaborators of S. Zildjian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Zildjian. S. Zildjian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study 2022 ·Annals of Oncology ·Anna V. Tinker, Bhavana Pothuri, (unknown), Renaud Sabatier, (unknown), Sharad Ghamande, Cara Mathews, David M. O’Malley, Valentina Boni, Adriano Gravina, Susana Banerjee, Rowan Miller, (unknown), Mansoor Raza Mirza, Tao Duan, (unknown), S. Zildjian, (unknown), Jennifer Veneris, Ana Oaknin	2
2	549P Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study 2022 ·Annals of Oncology ·(unknown), Dominique Berton-Rigaud, Giuseppe Curigliano, Renaud Sabatier, Anna V. Tinker, Ana Oaknin, Filippo de Braud, Susan Ellard, H-T. Arkenau, J.M. Trigo Perez, Jennifer G. Brown, Andrea Jewell, (unknown), Mansoor Raza Mirza, Tao Duan, (unknown), S. Zildjian, (unknown), Jennifer Veneris, Susana Banerjee	0
3	Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. 2022 ·Journal of Clinical Oncology ·Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, (unknown), Adriano Gravina, Emiliano Calvo, Susana Banerjee, Rowan Miller, Joanna Pikiel, (unknown), Tao Duan, S. Zildjian, (unknown), (unknown), Anna V. Tinker	15
4	547P Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study 2022 ·Annals of Oncology ·Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jennifer G. Brown, Sharad Ghamande, Cara Mathews, David M. O’Malley, Valentina Boni, Adriano Gravina, Susana Banerjee, Robert F. Miller, (unknown), Mansoor Raza Mirza, Tao Duan, (unknown), S. Zildjian, (unknown), Jennifer Veneris, Anna V. Tinker	1
5	Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study. 2022 ·Journal of Clinical Oncology ·Thierry André, Dominique Berton, Giuseppe Curigliano, (unknown), Susan Ellard, Adriano Gravina, Rowan Miller, Anna V. Tinker, Andrea Jewell, Joanna Pikiel, Ana Oaknin, Tao Duan, S. Zildjian, (unknown), Jennifer Veneris, Susana Banerjee	7
6	Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). 2014 ·Journal of Clinical Oncology ·Anastasios Stathis, Kami J. Maddocks, Ian W. Flinn, (unknown), Maria Lia Palomba, S. Zildjian, Mary Murphy, Jutta Deckert, Rodrigo Ruiz‐Soto, Arnold S. Freedman	7
7	A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) 2014 ·Blood ·Anastasios Stathis, Arnold S. Freedman, Ian W. Flinn, Kami J. Maddocks, Steven Weitman, Jesús G. Berdeja, (unknown), Emanuele Zucca, Rebecca Green, Angela Romanelli, S. Zildjian, Rodrigo Ruiz-Soto, Lia Palomba	14
8	Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. 2011 ·Journal of Clinical Oncology ·Penella J. Woll, Kraig Moore, Shailender Bhatia, Frank V. Fossella, (unknown), Mary O’Brien, Paul Lorigan, Steven Weitman, James J. O’Leary, S. Zildjian, Eileen M. Bulger, (unknown), Manisha H. Shah	13
9	Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). 2011 ·Journal of Clinical Oncology ·(unknown), Sikander Ailawadhi, Steven Weitman, S. Zildjian, James J. O’Leary, (unknown), (unknown), Kathleen R. Whiteman, Asher Chanan-Khan	27
10	Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination 2010 ·Blood ·Jesús G. Berdeja, Sikander Ailawadhi, Rubén Niesvizky, Jeffrey L. Wolf, S. Zildjian, James J. O’Leary, Asher Chanan‐Khan	12
11	Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis 2010 ·Blood ·Asher Chanan‐Khan, Jeffrey L. Wolf, Juan Garcia, Mecide Gharibo, Sundar Jagannath, (unknown), Taimur Sher, (unknown), S. Zildjian, James J. O’Leary, Robert Vescio	32
12	Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC) 2009 ·Journal of Thoracic Oncology ·Frank V. Fossella, Penella J. Woll, Paul Lorigan, (unknown), Mary O’Brien, (unknown), S. Zildjian, Albert Qin, James J. O’Leary, Miguel A. Villalona‐Calero	8
13	Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis. 2009 ·Blood ·Asher Chanan‐Khan, Jeffrey L. Wolf, Mecide Gharibo, Sundar Jagannath, Nikhil C. Munshi, Kenneth C. Anderson, (unknown), Kelvin P. Lee, Kena C. Miller, (unknown), S. Zildjian, Albert Qin, James J. O’Leary, Robert Vescio	17
14	A phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal (GE) junction cancer 2009 ·Journal of Clinical Oncology ·Laura W. Goff, K. Papadopoulos, James Posey, Alexandria T. Phan, Amita Patnaik, (unknown), S. Zildjian, James J. O’Leary, Albert Qin, Anthony W. Tolcher	13
15	Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma 2008 ·Blood ·Asher Chanan‐Khan, Mecide Gharibo, Sundar Jagannath, Nikhil C. Munshi, Kenneth C. Anderson, (unknown), Kelvin P. Lee, Kena C. Miller, (unknown), S. Zildjian, Albert Qin	8
16	The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Robert J. Lutz, (unknown), S. Zildjian, Akira Mita, Alexandria T. Phan, A. W. Tolcher	4
17	514 POSTER A novel dosing strategy based on plasma levels of CanAg in a Phase II study of IMGN242 (HUC242-DM4) in gastric cancer 2008 ·European Journal of Cancer Supplements ·A. W. Tolcher, (unknown), (unknown), (unknown), (unknown), S. Zildjian, (unknown), Alain C. Mita, (unknown)	1
18	A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors 2007 ·Molecular Cancer Therapeutics ·Kamalesh K. Sankhala, Alain C. Mita, Alejandro D. Ricart, Monica Mita, (unknown), Leslie Wood, John Sarantopoulos, Chris H. Takimoto, Amita Patnaik, Albert Qin, S. Zildjian, (unknown)	2
19	Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma 2007 ·Journal of Clinical Oncology ·John McCann, Frank V. Fossella, Miguel A. Villalona‐Calero, A. W. Tolcher, Panos Fidias, (unknown), S. Zildjian, (unknown), Robert J. Fram	12
20	649 POSTER Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors 2006 ·European Journal of Cancer Supplements ·Paul Lorigan, Penella J. Woll, (unknown), (unknown), S. Zildjian, (unknown), (unknown), (unknown), (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact